Compound sixty has an extremely higher affinity to MDM2 (Ki < one nM), powerful mobile activity, and a very good oral pharmacokinetic profile. Compound 60 is able to achieving finish and very long-Long lasting tumor regression in vivo and is also currently in section I clinical trials for cancer cure. https://grahamp741mdj1.wikisona.com/user